The Journal of the American Academy of Orthopaedic Surgeons · 2025
Preoperative Cannabis Use Is Associated With Elevated Risk for Complications and Revision Surgery After Anterior Cervical Diskectomy and Fusion.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tummala Sri, Sontam Tarun R, Noor Jason, Gibbs David C, Rizkalla James M, Avramis Ioannis
Аннотация
BACKGROUND: Cannabis use has increased markedly in recent decades, with US adult usage doubling from 4.1% to 9.5% between 2001 and 2013, and 43% of young adults reporting use by 2021. As legalization expands and cannabis becomes more mainstream, its perioperative implications have become clinically relevant. Although the orthopaedic literature has begun exploring the effect of cannabis use, its effect on anterior cervical diskectomy and fusion (ACDF) remains underinvestigated. Given the widespread adoption of ACDF and the projected rise in spinal procedures, understanding cannabis-related risks is essential to optimizing surgical outcomes.
METHODS: This retrospective cohort study used the TriNetX Research Network to identify patients undergoing primary ACDF from 2003 to 2023. Patients with cannabis use within 3 months before surgery were compared with matched nonusers using 1:1 propensity-score matching across key demographics and comorbidities. Outcomes included 90-day medical complications and healthcare utilization, as well as 2-year surgical outcomes including revision surgery, pseudarthrosis, and implant failure.
RESULTS: After matching (n = 2,169 per group), cannabis users demonstrated significantly higher 90-day rates of dysphagia (7.10% vs. 5.40%, P = 0.03), infection (1.60% vs. 0.90%, P = 0.04), postprocedural pain (7.20% vs. 4.10%, P < 0.001), opioid use (48.0% vs. 25.0%, P = 0.03), and readmission (3.90% vs. 2.70%, P = 0.04). At 2 years, cannabis users had higher rates of revision surgery (7.82% vs. 5.15%, P = 0.001), pseudarthrosis (10.10% vs. 8.25%, P = 0.04), and implant failure (4.31% vs. 2.78%, P = 0.01).
CONCLUSION: Preoperative cannabis use is associated with higher rates of medical and surgical complications, as well as an increased risk of revision surgery after ACDF. With cannabis use projected to rise markedly among surgical patients, these findings highlight its potential role as a modifiable risk factor, similar to tobacco use. Recognizing this association, incorporating evidence-based risk stratification, cannabis cessation counseling, and optimized perioperative care pathways may help reduce complication rates and improve fusion outcomes in patients undergoing ACDF.
METHODS: This retrospective cohort study used the TriNetX Research Network to identify patients undergoing primary ACDF from 2003 to 2023. Patients with cannabis use within 3 months before surgery were compared with matched nonusers using 1:1 propensity-score matching across key demographics and comorbidities. Outcomes included 90-day medical complications and healthcare utilization, as well as 2-year surgical outcomes including revision surgery, pseudarthrosis, and implant failure.
RESULTS: After matching (n = 2,169 per group), cannabis users demonstrated significantly higher 90-day rates of dysphagia (7.10% vs. 5.40%, P = 0.03), infection (1.60% vs. 0.90%, P = 0.04), postprocedural pain (7.20% vs. 4.10%, P < 0.001), opioid use (48.0% vs. 25.0%, P = 0.03), and readmission (3.90% vs. 2.70%, P = 0.04). At 2 years, cannabis users had higher rates of revision surgery (7.82% vs. 5.15%, P = 0.001), pseudarthrosis (10.10% vs. 8.25%, P = 0.04), and implant failure (4.31% vs. 2.78%, P = 0.01).
CONCLUSION: Preoperative cannabis use is associated with higher rates of medical and surgical complications, as well as an increased risk of revision surgery after ACDF. With cannabis use projected to rise markedly among surgical patients, these findings highlight its potential role as a modifiable risk factor, similar to tobacco use. Recognizing this association, incorporating evidence-based risk stratification, cannabis cessation counseling, and optimized perioperative care pathways may help reduce complication rates and improve fusion outcomes in patients undergoing ACDF.